Company Update: Eli Lilly & Company (NYSE:LLY) – Lilly Diabetes Helps Inspiring Students with Type 1 Diabetes Attend College Through Scholarship Donation

[PR Newswire] – ROLLING MEADOWS, Ill. and INDIANAPOLIS, Feb. 11, 2016 /PRNewswire/ — Attending college is a major milestone for many young people, but for those with type 1 diabetes, the journey can be extra demanding. Not only do these students juggle class schedules, assignments and campus activities, they also manage the daily challenges of living with type 1 diabetes. Lilly Diabetes understands and wants to help students with type 1 diabetes achieve their academic goals. Read more on this. Eli Lilly and Company (LLY) , valued at $75.63B, opened at $72.21. Looking at the equity, the company’s one day range is $70.83 to $72.66 and has traded between $68.31 and $92.85 over the past 12 months. Lilly (LLY) shares are currently priced at 20.96x this year’s forecasted earnings, which makes them relatively expensive compared to the industry ’s -6.04x earnings multiple for the same period. And for passive income investors, the company pays shareholders $2.04 per share annually in dividends, yielding 2.74%. In a review of the consensus earnings estimate this quarter, 16 sell-side analysts are looking at $0.84 per share, which would be $0.03 worse than the year-ago quarter and a $0.03 sequential decrease. Furthermore, our analysis shows the full-year EPS estimate to be $3.54, which would be a $0.11 better when compared to the last year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $4.83 Billion. If reported, that would be a 4.09% increase over the year-ago quarter. In terms of ratings, BMO Capital Markets upgraded LLY from Market Perform to Outperform (Nov 13, 2015). Previously, Credit Suisse upgraded LLY from Neutral to Outperform. The average price target for LLY shares is $98.90, which is 36.96% above where the stock opened this morning. See more in (NYSE:LLY) Similar Articles: Company Update (NYSE:LLY): J&J says its diabetes drug should have same survival edge as Lilly’s Market Update: Eli Lilly & Company (NYSE:LLY) – EXCLUSIVE-US insurers hold back Lilly’s death-defying diabetes drug Company Update (NYSE:LLY): Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events